Indole derivatives

• US 5,565,447 A
• Filed: 05/09/1995
• Issued: 10/15/1996
• Est. Priority Date: 07/28/1992
• Status: Expired due to Term

• Current Assignee: Almirall, S.A. (Grupo Corporativo Landon SL)
• Original Assignee: Laboratories Almirall SA (Grupo Corporativo Landon SL)
• Inventors: Noverola, Armando V., Mauri, Jacinto M., Duran, Carles P., Forner, Dolors F., Soto, Jose P.
• Primary Examiner(s): BERNHARDT, EMILY A
• Application Number:
  US08/437,682
• Time in Patent Office: 525 Days
• Field of Search: 548/467, 544/373, 546/201, 540/602, 514/212, 514/253, 514/323, 514/414
• US Class Current: 514/217.08
• CPC Class Codes: A61P 25/04 Centrally acting analgesics, e.g. opioids
• CPC Class Codes: A61P 25/06 Antimigraine agents
• CPC Class Codes: A61P 25/20 Hypnotics; Sedatives
• CPC Class Codes: A61P 25/24 Antidepressants
• CPC Class Codes: A61P 25/26 Psychostimulants, e.g. nicotine, cocaine
• CPC Class Codes: C07D 209/16 Tryptamines

Abstract

A compound of formula (I) ##STR1## wherein R¹ and R² each represents a hydrogen atom or an alkyl group, Z represents a ring selected from: ##STR2## in which n represents 4, 5 or 6; ##STR3## in which R³ represents hydrogen or an alkyl group and R⁴ represents an alkyl, methoxy benzyl or R⁵ NHCO group, R⁵ being an alkyl group; and ##STR4## in which R⁶ represents an alkyl group. and pharmaceutically acceptable salts thereof are useful in the treatment of migraine and other conditions. They are prepares by decarboxylation of the corresponding indolyl 2-carboxylic acid.

Claims

1. A compound of formula (I) ##STR11## wherein R¹ and R² each represents a hydrogen atom or a C_1-6 alkyl group, Z represents a ring selected from:

##STR12## in which n represents 4, 5 or 6;

##STR13## in which R.sup. 6 represents a C_1-6 alkyl group, or pharmaceutically acceptable salts thereof.

2. A compound according to claim 1 in which R¹ and R² which by the same or different is each C_1-4 alkyl, and Z is of the formula II.

4. A composition comprising a compound according to claim 1 mixed with a pharmaceutically acceptable carrier or diluent.

5. A method of treating headaches, movement disorders, depression or anxiety which comprises administering to a human or animal subject in need of treatment of an effective amount of a compound according to claim 1.

6. A method according to claim 5 wherein said treatment is for a migraine.

3. 1-[[3-(2-dimethylaminoethyl)-5-indolyl]methanesulphonyl]pyrrolidine;

1-[[3-(2-dimethylaminoethyl)-5-indolyl]methanesulphonyl]piperidine;

or

1-[[3-(2-dimethylaminoethyl)-5-indolyl]methanesulphonyl]-4-ethoxycarbonyl piperazine;

or a hydrochloride salt thereof.